Evercore analyst Elizabeth Anderson CFA maintains $McKesson (MCK.US)$ with a buy rating, and adjusts the target price from $630 to $680.
According to TipRanks data, the analyst has a success rate of 38.0% and a total average return of -8.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $McKesson (MCK.US)$'s main analysts recently are as follows:
The shares of McKesson experienced a 5% increase following a solid financial performance that countered the prevailing skeptical view on the company's long-term targets.
The firm commented that McKesson exhibited strong performance across all segments, with particularly robust results in US Pharma during the second quarter. Furthermore, the guidance suggests an anticipation of segment EBIT growth acceleration in FY25, which the firm finds encouraging.
McKesson has addressed several concerns and eliminated a number of significant obstacles. The company, along with its peers, has consistently reported robust updates. Large-cap healthcare stocks are notably under-represented in portfolios and are comparatively undervalued. There seems to be no compelling reason why the company would not re-approach its recently higher valuation multiples.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Elizabeth Anderson CFA維持$麥克森 (MCK.US)$買入評級，並將目標價從630美元上調至680美元。
根據TipRanks數據顯示，該分析師近一年總勝率為38.0%，總平均回報率為-8.0%。
此外，綜合報道，$麥克森 (MCK.US)$近期主要分析師觀點如下：
麥克森的股價上漲了5％，此前其穩健的財務表現打破了對公司長期目標的普遍懷疑態度。
該公司評論說，麥克森在所有細分市場均表現強勁，第二季度美國製藥業的業績尤其強勁。此外，該指導方針表明，預計25財年細分市場的息稅前利潤增長將加速，該公司認爲這令人鼓舞。
麥克森已經解決了幾個問題，並消除了許多重大障礙。該公司及其同行一直報告強勁的更新。大盤醫療保健股在投資組合中的代表性明顯不足，而且估值相對低估。該公司似乎沒有令人信服的理由不重新計算最近更高的估值倍數。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
